FDA grants priority review for Amgen's sBLA for Repathaź (evolocumab)
Amgen announced the FDA has granted priority review for Amgen's sBLA for Repathaź (evolocumab), a PCSK9 inhibitor. If approved by the FDA, the Prescribing Information will be updated to include risk reduction of major cardiovascular events based on data from the large FOURIER study. July 27, 2017